Genmab A/S Surges After Analyst Sparks GlaxoSmithKline Speculation

Bloomberg -- Genmab A/S rose the most in almost two years in Copenhagen trading after an analyst said the biotechnology company is undervalued, making it a takeover target for GlaxoSmithKline Plc.

MORE ON THIS TOPIC